Abstract
Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Current Drug Targets
Title: Prophylactic Neuroprotection
Volume: 8 Issue: 7
Author(s): Sean I. Savitz and Marc Fisher
Affiliation:
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Abstract: Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Export Options
About this article
Cite this article as:
Sean I. Savitz and Marc Fisher , Prophylactic Neuroprotection, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077382
DOI https://dx.doi.org/10.2174/138945007781077382 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Chemotherapeutic Approaches Against Trypanosoma evansi: Retrospective Analysis, Current Status and Future Outlook
Current Topics in Medicinal Chemistry Enhanced Expression of miR-199b-5p Promotes Proliferation of Pancreatic β-Cells by Down-Regulation of MLK3
MicroRNA Inorganic Engineered Nanoparticles and Their Impact on the Immune Response
Current Drug Metabolism Current Directions in Non-Invasive Low Intensity Electric Brain Stimulation for Depressive Disorder
CNS & Neurological Disorders - Drug Targets In vivo Piroxicam Metabolites: Possible Source for Synthesis of Central Nervous System (CNS) Acting Depressants
Central Nervous System Agents in Medicinal Chemistry Dimebon Attenuates the Aβ-Induced Mitochondrial Permeabilization
Current Alzheimer Research Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?
Current Clinical Pharmacology Research Advancements in Porcine Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Synthesis and Biological Applications of Triazole Derivatives – A Review
Mini-Reviews in Organic Chemistry Magnetic Nanoparticles: Properties, Synthesis and Biomedical Applications
Current Drug Metabolism Calpain and Its Involvement in the Pathophysiology of CNS Injuries and Diseases: Therapeutic Potential of Calpain Inhibitors for Prevention of Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Dual Effects of Antioxidants in Neurodegeneration: Direct Neuroprotection against Oxidative Stress and Indirect Protection via Suppression of Gliamediated Inflammation
Current Pharmaceutical Design